Rechercher un essai clinique
Autre(s) option(s) de recherche
62 Résultat(s)
Essai en cours de recrutement = 
; Essai en cours = 
; Financé par un membre IRDiRC = 
; Membre d'un ERN = 
Essai(s) clinique(s) national(aux)
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Response of CV-MG01, Acetylcholine Receptor Mimetic Peptides, as Potential Therapeutic Vaccine, in Patients With Myasthenia Gravis
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MesaCapp: Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome (Phase 2) - AT
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) - US
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Étude de phase 1b, randomisée, en double aveugle, contrôlée par placebo visant à évaluer l'innocuité, la tolérabilité et la pharmacocinétique du QR-010 chez des sujets atteints de fibrose kystique porteurs homozygotes de la mutation DeltaF508 - BE
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
JIKI: Efficacy of Favipiravir in Reducing Mortality in Individuals With Ebola Virus Disease in Guinea (Phase II)
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study -DE-
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia (Phase III) - ES (completed)
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study (Phase III) - ES
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VISION DMD: Étude de phase IIb randomisée, en double aveugle, en groupe parallèle, contrôlée par placebo et active avec extension en double aveugle pour évaluer l'efficacité et l'innocuité de la vamorolone chez des garçons en ambulatoire atteints de dystrophie musculaire de Duchenne
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea (Ebola-Tx) (completed)
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DENIM: Étude de phase II/III randomisée et ouverte portant sur des cellules dendritiques chargées de lysat de cellules tumorales allogéniques (PheraLys) chez des sujets atteints de mésothéliome en tant que traitement de maintenance (MesoPher) après une chimiothérapie- BE
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Subjects Affected by Acanthamoeba Keratitis - PL
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MIROCALS : Efficacité, pharmacodynamie et sécurité de l'interleukine-2 à faible dose (ld-IL-2), en tant que stimulant des lymphocytes T régulateurs (Tregs) à visée thérapeutique anti-neuro-inflammatoire, chez des patients présentant une Sclérose Latérale Amyotrophique (SLA) nouvellement disgnostiquée : un essai randomisé, contrôlé, mené en double aveugle (Phase II) - FR
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DENIM: Étude de phase II/III randomisée et ouverte portant sur des cellules dendritiques chargées de lysat de cellules tumorales allogéniques (PheraLys) chez des sujets atteints de mésothéliome en tant que traitement de maintenance (MesoPher) après une chimiothérapie - FR
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Etude exploratoire ouverte d'évaluation de l'efficacité de QR-010 sur les différences de potentiel nasal (DDP) de patients atteints de mucoviscidose homozygote ou hétérozygote composites pour la mutation F508del (Phase I) - FR
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Étude de Phase 1b, randomisée, en double aveugle, contrôlée par placebo, à escalade de dose pour évaluer la sécurité, la tolérance et la pharmacocinétique de QR-010 chez des sujets adultes atteints de mucoviscidose homozygote pour la mutation F508del - FR
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis - GB
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NICOFA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia - AT
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis- IT
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - IE
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GLIOMARK1: Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis -DE-
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Treg Therapy: Treatment of steroid-resistant chronic graft-versus-host-disease with donor-derived regulatory T cells
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NICOFA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia-GB
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MCDS-Therapy: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children-GB
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MCDS-Therapy: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children - BE
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NISCI: Antibodies Against Nogo-A to Enhance Plasticity, Regeneration and Functional Recovery After Spinal Cord Injury - A Multicenter International Randomized Double Blind Placebo Controlled Phase II Clinical Proof of Concept Trial - CH
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (Phase 1)
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MCDS-Therapy: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children - DE
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - BE
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study -DE-
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - DE-
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IE
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VISION DMD: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) - ES
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - DE
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IT
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUROSHOCK: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock - AT
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUROSHOCK: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock - ES
European Commission
DG Research - Directorate General for Research
Essai(s) clinique(s) multinational(aux)
ALLEMAGNE
Nordrhein-Westfalen
AACHEN
NICOFA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia
Universitätsklinikum Aachen
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the deltaF508 CFTR Mutation
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VISION DMD: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Exploratory Phase II Study in Patients After Treatment of High Grade Brain Tumors to Assess the Technical Performance of Tc-99m Tetrofosmin for Differentiation of Recurrence Versus Radiation Necrosis
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BOOSTB4: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls.
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NICOFA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia
European Commission
DG Research - Directorate General for Research
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care.
European Commission
DG Research - Directorate General for Research
ETATS-UNIS
Maryland
ROCKVILLE
VISION DMD: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
ReveraGen BioPharma, Inc.
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
VISION DMD: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
Institution: Information not provided - US
GRECE
ATTIKI
MAROUSI
GRECE
GREECE
ADDRESS: NOT PROVIDED - GR
Exploratory Phase II Study in Patients After Treatment of High Grade Brain Tumors to Assess the Technical Performance of Tc-99m Tetrofosmin for Differentiation of Recurrence Versus Radiation Necrosis
Institution: Information not provided - GR
ITALIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study
Institution: Information not provided - IT
ITALIE
MARCHE
URBINO
ITALIE
SICILIA
ACI S. ANTONIO
Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis
Società Industria Farmaceutica Italiana S.p.A.(S.I.F.I.)
PAYS-BAS
Zuid-Holland
LEIDEN
Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the deltaF508 CFTR Mutation
ProQR Therapeutics N.V.
PAYS-BAS
Zuid-Holland
LEIDEN
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis
ProQR Therapeutics N.V.
ROYAUME-UNI
Greater London
LONDON
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care.
King's College London
King's College London Headquarters
ROYAUME-UNI
Greater London
LONDON
SUEDE
Region Stockholm
ADDRESS: NOT PROVIDED - SE
BOOSTB4: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls.
Institution: Information not provided - SE
SUEDE
Region Stockholm
STOCKHOLM
BOOSTB4: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls.
Karolinska Universitetssjukhuset - Huddinge
Karolinska University Hospital
SUEDE
Region Stockholm
STOCKHOLM